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Abstract 
Background: Oral lichen planus (OLP) is a common chronic inflammatory mucosal disease with a multifactorial 
etiology. It is a T-cell mediated autoimmune disease in which the cytotoxic CD8+T cells trigger apoptosis of the 
basal cells of oral epithelium. Various treatment regimens have been employed for management of symptomatic 
OLP. This study was carried out to evaluate the effect of topical steroids as well as laser on the clinical signs and 
symptoms detected by reticular, atrophic, erosive score (RAE score) and tumor necrosis factor- α (TNF-α) level in 
the serum of patients with symptomatic OLP.
Material and Methods: The study was conducted on twenty-four patients (18 females and 6 males) with sympto-
matic OLP that were allocated into two groups. Each included twelve patients. The first group treated either with 
diode laser (970nm SIROLaser Advance class IIIb, SIRONA The Dental Company, Germany) twice weekly with 
maximum of ten sessions while the second group were treated with topical corticosteroids (0.1% triamcinolone 
acetonide orabase, Kenacort-A Orabase Pomad, DEVA HOLDING A.Ș, Istanbul, Turkey) for four weeks. 
Results: Corticosteroids group showed less clinical signs and symptoms of reticular, atrophic, erosive RAE score 
(p=0.02) and TNF-α serum level (p=0.028) than diode laser group with no reported therapy side effects or compli-
cations in any of the treated patients. 
Conclusions: Topical steroids reduce pain, reticular, atrophic, erosive RAE score and TNF-α serum level more than 
laser treatment. Moreover, laser treatment can be used as an alternative treatment when steroids are contraindicated 
for the treatment of symptomatic OLP.
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Introduction
Oral lichen planus (OLP) is an inflammatory mucocu-
taneous disorder of an autoimmune disease. A reported 
prevalence of 1.27% commonly in women aged between 
30 and 60 years (1). In a recent study in Egypt revealed 
a prevalence of 1.43% among the Egyptians (2). OLP 
are mostly polymorphic such as reticular type which is 
present as white striae known as Wickham’s striae often 
bilateral and asymptomatic. Erosive/atrophic (OLP) pre-
sent as irregular ulceration, often associated with pain 
and burning sensation which is exacerbated by trauma, 
hot, spicy and acidic food (3). OLP pathogenesis is 
thought to be a T-cell mediated autoimmune disease in-
volving specific and non-specific antigen specificity (4). 
Antigen specificity includes antigen presentation by ba-
sal keratinocytes and antigen-specific keratinocytes by 
CD8+cytotoxic T-lymphocytes whereas non-specific an-
tigen includes mast cell degranulation and matrix meta-
lloproteinase activation (5). Interleukin-6 (IL-6), Tumor 
necrosis factor-α (TNF-α) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) release and pro-
voke the local inflammatory response (6). Compared 
with other cytokines TNF-α is the most extensive in 
OLP, it was consistently observed in OLP when compa-
red with non-lesional or normal oral mucosa (7). Varia-
ble treatments were used such as cyclosporine, extracor-
poreal photochemotherapy, pimecrolimus and tacrolimus 
(8). Corticosteroids are the main effective drugs of choice 
for the treatment of symptomatic OLP (9). Topical corti-
costeroids used in long-time induce insensitivity drug to-
lerance (10), pseudomembranous candidiasis, and adrenal 
insufficiency (11). Furthermore, some patients are allergic 
to corticosteroids while others are insensitive, or even re-
sistant to corticosteroids (12). Recently, novel effective 
treatments were introduced for treating erosive OLP with 
minimal side effects as Laser Therapy (13). This study 
aimed to compare the effect of topical corticosteroid ver-
sus diode Laser irradiation in the treatment of oral lichen 
planus by investigating the serum level of TNF-α. 
Material and Methods
The present study carried out on twenty four patients (18 
females, 6 males) with age range from 35-70 years. Pa-
tients were recruited from outpatient clinic of Oral Me-
dicine and Periodontology Department, Faculty of Oral 
and Dental Medicine, Cairo University. The laser group 
patients were treated in outpatient Dental Clinic in Na-
tional Research Center. The study protocol was appro-
ved by Ethical Committee of Faculty of Oral and Dental 
Medicine, Cairo University.
-Inclusion criteria
Patients diagnosed with OLP were included in the study 
based on WHO criteria, if any of them suffered from dia-
betes and/or hypertension, the condition was controlled 
before being included in the study.
-Exclusion criteria
Smokers, pregnant and lactating ladies, those with history 
of topical steroids during the last two months, systemic ste-
roids during the last six months. Patients with uncontrolled 
diabetes or hypertension, positive HCV Ab or HBs Ag.
-Clinical evaluation
The clinical data were scored according to the criteria 
scale used by Thongprasom et al. (14); score 5: white 
striae with erosive area >1 cm2, score 4: white striae with 
erosive area <1 cm2, score 3: white striae with atrophic 
area >1 cm2, score 2: white striae with atrophic area <1 
cm2, score 1: mild white striae only; score 0: no lesions 
or normal mucosa. The size of the lesions was measu-
red using William’s graduated periodontal probe. For 
patients with more than one lesion, a sign score was de-
rived by summation of the scores of all areas: Reticu-
lar score =Σ R, Atrophic score =Σ A, Erosive/ulcerative 
score =Σ E with a total weighted score of Σ (R x1)‏ +Σ 
(A x 1.5) ‏+Σ (E x 2.0) and this score was called RAE 
score (15). Total improvement (total resolution of the 
clinical signs) was defined as the disappearance of all 
atrophic-erosive lesions, regardless of any persisting hy-
perkeratotic lesions; Partial response, meant a decrease 
in the patient RAE score compared to baseline; and no 
improvement defined as no change at all in the patient’s 
score (16). Patients were categorized into two groups: 
Group (I): It included twelve patients, eight females and 
four males with age range of 35-70 years. They were 
subjected to laser sessions twice weekly. Group (II): 
It included twelve patients, ten females and two males 
with age range of 45-62 years. They were treated with 
topical corticosteroids (0.1% triamcinolone acetonide 
orabase, Kenacort-A Orabase Pomad, DEVA HOLDING 
A.Ș, Istanbul, Turkey). Before treatment improvement 
of the oral hygiene, professional scaling were done for 
all patients, and oral hygiene instructions were given to 
reduce the local bacterial load and plaque accumulation. 
Before laser therapy, normal protective measures were 
taken. All personnel as well as the patient wore laser 
safety eye glasses. A gallium-aluminum-arsenide (GaA-
lAs) diode laser (970nm SIROLaser Advance class IIIb, 
SIRONA. The Dental Company, Germany) was used. 
The areas of the lesions were irradiated plus a 3mm mar-
gin beyond the visible lesions, using a laser device with 
2W irradiation power in a continuous-wave (CW) in a 
non-contact mode. The exposure time used was eight 
minutes in four subsequent sessions each with one mi-
nute in between to allow for tissue relaxation. The laser 
beam was delivered using a fiber-optic tip with 320µm 
diameter. Irradiation was done two times a week for 
a maximum of ten sessions. After each laser session, 
a cold diet was recommended and the patient was ad-
vised to use chlorhexidine oral gel post-operatively. 
No side-effects were observed at any time during the 
treatment and follow-up. In the second group patients 
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were instructed to apply the medication for four times 
per day, with no food or fluid after administration for a 
minimum of one hour post-application. They used the 
medication for maximum of four weeks. Those who 
extend the treatment to the fourth week were instruc-
ted to apply miconazole oral gel to avoid superimposed 
fungal infection. 
-Immunohistochemical analysis
Five milliliter venous blood was withdrawn from both 
patients’ groups before and after treatment. All blood 
samples were centrifuged after 30 minutes from their 
collection. They were then stored in -20°C temperatu-
re until laboratory analysis carried on. Quantitation of 
TNF-α in serum was done by using TNF-α ELISA Kit 
provided by AviBion, Helsinki FINLAND. 
-Statistical analysis
Numerical data were explored for normality by checking 
the distribution of data, calculating the mean and median 
values as well as using tests of normality (Kolmogorov-
Smirnov and Shapiro-Wilk tests). Age data showed pa-
rametric distribution while pain scores and TNF-α levels 
data showed non-parametric distribution. Data were 
presented as mean and standard deviation (SD) values. 
For parametric data; Student’s t-test was used to com-
pare between the two groups. For non-parametric data; 
Mann-Whitney U test was used to compare between 
the two groups. Wilcoxon signed-rank test was used 
to compare between pre- and post-treatment values in 
each group. Friedman’s test was used to compare bet-
ween pre-, post-treatment and after exacerbation values 
in each group. Wilcoxon signed-rank test was used for 
pair-wise comparisons when Friedman’s test is signifi-
cant. Bonferroni’s correction was applied for the pair-
wise comparisons. Qualitative data were presented as 
frequencies (n) and percentages (%). Chi-square test 
was used to compare between the two groups. The sig-
nificance level was set at P ≤ 0.05. Statistical analysis 
was performed with IBM (IBM Corporation, NY, USA), 
SPSS (SPSS, Inc., an IBM Company) Statistics Version 
20 for Windows.
Fig. 1. Pre-treatment, there was no statistically significant difference 
regarding the mean RAE score between the two groups. Post-treat-
ment, Corticosteroids group showed statistically significantly lower 
mean RAE score than Laser group (P= 0.02) 
Results
-Comparison between the two groups (pre, post treatment 
and at follow up) regarding the Reticular, Atrophic, Ero-
sive clinical scores.
Pre-treatment, there was no statistically significant di-
fference regarding the mean RAE score between the two 
groups. Post-treatment, Corticosteroids group showed 
statistically significantly lower mean RAE score than 
Laser group (P= 0.02) (Fig. 1). At follow up, there was 
no statistically significant difference regarding the mean 
RAE score between the two groups (Table 1).
-Comparison between the two groups (after exacerba-
tion).
After exacerbation, there was no statistically significant 
difference between the two groups (Table 2, Fig. 2). 
-TNF-α levels Comparison between the two groups pre, 
post treatment and at the follow up. 
Pre-treatment, there was no statistically significant di-
fference between the two groups. Post-treatment, Corti-
costeroids group showed statistically significantly lower 
mean TNF-α levels than Laser group (P= 0.028) (Fig. 
3). At follow up, there was no statistically significant di-
fference between the two groups (Table 3).
Time Corticosteroids 
(n=12) 
Laser  
(n=12) 
P-value
Mean SD Mean SD 
Pre-treatment 21.6 11.8 28.5 11.7 0.150 
Post-treatment 6.0 7.9 16.1 15.8 0.020* 
Follow up 2.8 1.0 10.5 0.7 0.060 

Table 1. Mean standard deviation (SD) values and results of comparison between RAE clinical 
scores in the two groups.
*: Significant at P ≤ 0.05.
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Time Corticosteroids  
(n=3) 
Laser 
(n=2) 
P-value
Mean SD Mean SD  
After exacerbation 21.5 13.5 11.3 8.1 0.248 

Table 2. Mean standard deviation (SD) values and results of comparison between Reticular, Atrophic, and 
Erosive clinical score in the two groups after exacerbation.
*: Significant at P ≤ 0.05.
Fig. 2. After exacerbation, there was no statistically significant dif-
ference between the two groups.
Fig. 3. Pre-treatment, there was no statistically significant differ-
ence between the two groups. Post-treatment, Corticosteroids group 
showed statistically significantly lower mean TNF-α levels than La-
ser group (P= 0.028).
Time Corticosteroids  
(n=12) 
Laser 
(n=12) 
P-value
Mean SD Mean SD  
Pre-treatment 37.4 4.7 36.1 5.2 0.653 
Post-treatment 17.6 3.4 25.7 9.2 0.028* 
At follow up 23.8 11.5 28.0 3.6 0.199 

Table 3. Mean standard deviation (SD) values and results of comparison between TNF-α level in the two 
groups.
*: Significant at P ≤ 0.05.
Discussion
Etiologic factors causing OLP are genetic factors, au-
toimmune, infectious agent, stress, diabetes, hyperten-
sion and malignant neoplasm (5). Corticosteroids are 
the most common group of drugs for the treatment of 
symptomatic OLP due to the fact of their ability to mo-
dulate inflammation and immune response by reducing 
the lymphocytic exudate and stabilization the lysosomal 
membrane (17). OLP patients unresponsive to topical 
superpotent corticosteroids, surgical management using 
cryosurgery and different types of laser were tried. A 
980-nm diode laser; CO2 laser evaporation (18); low-
dose excimer 308-nm laser with UV-B rays (19) and 
biostimulation with a pulsed diode laser using 904-nm 
pulsed infrared rays have been tried (20). It was believed 
that laser acts by local stimulation of the diseased tissues 
by improving the local microvasculature (21), reducing 
the amount of inflammatory mediators, increasing cellu-
lar activity, increasing the quantity of granulation tissue 
and hence, stimulating the normal physiologic healing 
process (22). This may be attributed to stimulation of 
vascular smooth muscles relaxation (22). It is postulated 
that laser enhances β-endorphin and encephalin relea-
se in tissues, inhibits prostaglandin E2 production, and 
improves blood flow and lymphatic drainage, and de-
crease edema (23), many recent studies are investigating 
the application of LLLT for treatment of OLP (24). The 
wavelength selected was 970-nm since it allows super-
ficial action from an optical point of view. The exposure 
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time used was 4 minutes; this duration was decided after 
pilot study on four patients. It aimed to achieve maxi-
mum benefit without any laser side effects. The laser 
group of patients assisted 2 sessions weekly as recom-
mended by Kazancioglu et al. (24). The serum TNF-α 
level is proposed to increase in OLP patients in contrast 
to healthy people (25); and therefore TNF-α was evalua-
ted in this study and considered as an indicator for OLP 
disease activity. Several studies have proved the anal-
gesic effect of soft laser in acute (25) and chronic pain 
of various etiopathogenesis (26). It is well known that 
corticosteroids reduce pain by the inhibitory effect on 
the phospholipase enzyme, preventing the conversion of 
phospholipids into arachidonic acid critical for prosta-
glandins production (27). In the laser group, statistically 
significant decrease in RAE post treatment (p=0.035) 
was found. This is coinciding with the results of Cafaro 
et al. (20) who showed significant clinical improvement 
(p=0.001). In this study, the group treated with topical 
steroids showed also statistically significant reduction 
in the RAE scores (p= 0.018). Nevertheless, topical ste-
roids group showed statistically significant lower mean 
scores than the laser group (p=0.02). In this study, low 
power laser improved microcirculation and promoted 
angiogenesis (25); this may explain the clinical impro-
vement achieved in patients treated with laser. On the 
other hand, improvement in the steroids group mostly 
depends on the inhibition of the inflammatory process of 
the disease allowing for physiologic tissue repair (27). 
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